SUBCHONDRAL SOLUTIONS RECEIVES BOOST FOR COMMERCIAL LAUNCH AFTER WIDESPREAD AAOS INTEREST

Subchondral Solutions, Inc., a medical device company based in Huntington Beach, Calif., received strong support for its S-Core platform technology™ from key opinion leaders at this year’s American Academy of Orthopedic Surgeons (AAOS) conference in San Diego. The support for the innovative platform further will further boost the commercial launch of the product.

“Our success at this year’s AAOS will strengthen our full commercial launch,” says Tom Kinder, CEO of Subchondral Solutions. “After meeting with doctors from all over the United States at the AAOS, we realized surgeons are prepared to use our platform now for their patients.”

Cleared by the FDA in 2020, the S-Core platform technology™ is indicated for fixation of small bone fragments, such as osteochondral fragments and cancellous fragments, appropriate for the size of the device which may include the following: simple metaphyseal fractures; condylar fractures; osteochondritis dissecans; areas where accurate screw placement is vital; patellar fractures, navicular fractures, cancellous bone fragments; osteochondral fragments, intra-articular fractures and osteochondral fixation and fractures, and minimally invasive reconstruction of fractures and joints. S-Core™ can be used in any osteochondral fracture appropriate for the size of the device, including for the knee, elbow, hand, foot, ankle, shoulder and hip.

 “We met with some of the most respected key opinion leaders and they are excited to begin using S-Core™,” said Jordan Peana, director of sales at Subchondral Solutions. “They recognize our bio-active implants will maximize bone and biologic healing.”